{"id":"cd19-t-hank-iv-administration","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Cytokine release syndrome"},{"rate":"20-30%","effect":"Neutropenia"},{"rate":"10-20%","effect":"Anemia"},{"rate":"10-20%","effect":"Thrombocytopenia"},{"rate":"10-20%","effect":"Infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CD19 t-haNK- is a chimeric antigen receptor (CAR) T-cell therapy that specifically targets cancer cells expressing the CD19 protein. This approach involves genetically modifying a patient's T-cells to recognize and bind to CD19, leading to the activation of the immune system and the subsequent destruction of cancer cells.","oneSentence":"CD19 t-haNK- is a type of immunotherapy that targets and kills cancer cells by harnessing the power of a patient's own immune system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:50:06.248Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory B-cell malignancies"}]},"trialDetails":[{"nctId":"NCT07477366","phase":"PHASE2","title":"Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2026-04","conditions":"Relapsed B-Cell Non-Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT07125872","phase":"PHASE2","title":"Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-11-11","conditions":"Relapsed B-Cell Non Hodgkin Lymphoma","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CD19 t-haNK- IV Administration","genericName":"CD19 t-haNK- IV Administration","companyName":"ImmunityBio, Inc.","companyId":"immunitybio-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"CD19 t-haNK- is a type of immunotherapy that targets and kills cancer cells by harnessing the power of a patient's own immune system. Used for Relapsed or refractory B-cell malignancies.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}